AIT shot patients- we will offer shots by appointment only on Tuesdays and Thursdays and Fridays

Please email us at arlingtonallergy@gmail.com or call our office at 703-558-6040 Mondays, Tuesdays, Thursdays or Friday mornings to schedule an appointment. Please follow the guidelines for AIT and biologic injections and allergy skin testing for AIT patients only.

If you are due for a refill please schedule a virtual appointment followed by allergy skin testing so we can make changes as needed to your formulation prior to mixing your refill.

We have begun to see patients in the office as well if you would like an in-person appointment. Must be asymptomatic, meaning no cough, fever, sore throat, or exposure to someone with COVID 19 or travel to area with high incidence of Covid 19.

Palforzia: FDA approved first drug for treatment of peanut allergy in children.

Palforzia:  FDA approved first drug for treatment of peanut allergy in children.

Jan 31st, the U.S. Food and Drug Administration approved Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp] to mitigate allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanuts. Treatment with Palforzia may be initiated in individuals ages 4 through 17 years with a confirmed diagnosis of peanut allergy and may be continued in individuals 4 years of age and older. Those who take Palforzia must continue to avoid peanuts in their diets….

https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treatment-peanut-allergy-children

More information on this podcast: https://www.aaaai.org/professional-education-and-training/podcasts

Dupixent available for asthma and eczema patients 6 and older

Dupixent (Dupilumab),  is a monoclonal antibody designed for the treatment of allergic diseases such as eczema and asthma by blockage of IL-4Rα, dupilumab modulates signaling of both the interleukin 4 and interleukin 13 pathways, which are allergic pathways.

Indicated for 6 and older for asthma and eczema contact our office if you are interested in a non-steroidal treatment for your child’s moderate to severe asthma or eczema.

Changes in Shot hours

SHOT HOURS: changed due to Covid 19-please check with our office.
Monday: 
Tuesday: 
Thursday:                                                                         Friday: 

Please follow us on Facebook for up to date changes and information.

CHANGE: [ modified above]* check for updates for changes in hours.

If these hours do not work with your schedule, please ask our front desk staff for the names of allergists where you can receive your injections. Some primary care offices will administer them as well as some urgent care centers.  This will require a visit with the allergist and if approved then you may receive your allergy injections only there. Your allergy and asthma care will still remain with our office.

 Please follow us on Facebook for up to date changes and information.

Peanut OIT Aimmune had late breaking news!

At the recent AAAAI allergy national and international meeting in Orlando had many highlights including the late breaking news that AIMMUNE the company researching and producing the peanut oral immunotherapy showed that 67% of the patients being treated were able to tolerate 600mg (about 2 peanuts) without severe reaction! Hoping this treatment will be FDA approved by 2019 and on the market by 2019-2020! Finally an FDA safe and effective treatment for peanut allergic patients may be just around the corner.

Odactra-Dustmite allergy treatment is available!

For patients with dust mite allergy who are looking to lessen their dust mite allergy symptoms without medication should consider Odactra, a sublingual tablet of concentrated dustmite protein to help teach your body’s immune system to tolerate dust mites. The first dose is taken in the office and then at home! It’s covered by insurance plans. See if you are a candidate, call to make an appointment (703) 558-6040.

Prevent peanut allergy

For infants at high risk, meaning they have eczema, food allergy, sibling with food allergy (especially peanut) or parents with allergies, the LEAP study showed that early introduction of peanut prevented a peanut allergy in most infants.

We offer an evaluation for these high-risk patients and if negative, then we can start patients safely on this preventative therapy and if borderline peanut reaction on allergy skin test, can offer a peanut challenge in the office.

Proper evaluation, dosing and frequency is important to make this therapy successful.